REGENSBURG, GERMANY--(Marketwire - July 01, 2008) - Regensburg, July 1, 2008 - GENEART AG, the global leader in gene synthesis and specialist in Synthetic Biology, is announcing an extension of the current agreement with the US National Cancer Institute (part of NIH, the American health authorities) by USD 0.8M. The NIH are therefore increasing the order volume for the production of genes for the "Mammalian Gene Collection (MGC)" to a total of USD 2.7M in 2008. More than 3,500 genes with an order volume of approximately USD 3.5M were produced by GENEART last year as part of the basic contract. The National Cancer Institute uses the genes synthesized by GENEART to supplement the Mammalian Gene Collection - a comprehensive collection of genes from mice, rats, and humans, both for basic research and for applied medical research.
